Intelgenx Technologies Corp
TSX:IGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Toyo Seikan Group Holdings Ltd
OTC:TOSKF
|
JP |
|
E
|
Equitrans Midstream Corp
F:37W
|
US |
|
K
|
Konsortium Transnasional Bhd
KLSE:KTB
|
MY |
|
O
|
Olympic Circuit Technology Co Ltd
SSE:603920
|
CN |
Intelgenx Technologies Corp
Other Items
Intelgenx Technologies Corp
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intelgenx Technologies Corp
TSX:IGX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other Items
-$188m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
36%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Other Items
CA$28.3m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
43%
|
|
|
Cronos Group Inc
TSX:CRON
|
Other Items
-$50.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other Items
-$186.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other Items
-CA$19.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
Intelgenx Technologies Corp
Glance View
IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. The company is headquartered in Saint-Laurent, Quebec. The company went IPO on 2008-05-23. The firm is focused on the development and manufacturing of pharmaceutical films. The firm's pharmaceutical film technologies include VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, which allows pharmaceutical products that address unmet medical needs. The firm's product pipeline offers various benefits to patients and physicians for many therapeutic conditions. Its VersaFilm research and development (R&D) services are based on a versatile drug delivery platform technology that enables the development of oral thin films exhibiting improved product performance. Its VetaFilm R&D services and veterinary oral films provide various market opportunities for improved drug delivery for companion animals. Its product portfolio includes RIZAPORT (Rizatriptan), EXORDIA (Tadalafil), Loxapine, Montelukast, Buprenorphine / Naloxone, and Dronabinol AdVersa (Dronabinol).
